Invasive Ductal Carcinoma Therapeutics Global Market Report 2025
상품코드:1769627
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
침윤성 유관암 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년의 연간 평균 성장률(CAGR)은 8.6%로 성장할 전망이며, 125억 5,000만 달러로 성장이 예측됩니다. 이 예측 기간의 성장은 맞춤형 치료 전략에 대한 기호 증가, 저침습 수술 수기에 대한 수요 증가, 바이오시밀러 모노클로날 항체의 승인 증가, 항체 약물 복합체의 임상 파이프라인 확대, 가치 기반의 암 치료 모델에 대한 주목 증가 등에 기인하고 있습니다. 예측 기간 동안 예상되는 주요 동향으로는 면역 체크포인트 저해제 개발, 영상 진단 및 치료 시스템 통합, 환자 관리에 대한 디지털 헬스 플랫폼 도입, 마이크로 RNA 모듈레이터 혁신, 나노입자 기반 약물 전달 시스템 발전 등이 있습니다.
유방암의 이환율 증가는 향후 수년간 침윤성 유관암 치료 시장의 성장을 가속할 것으로 예측됩니다. 유방암은 유방 내 세포가 통제 불능으로 증식해 악성 종양을 형성하고 인근 조직으로 침윤하거나 몸의 다른 부위로 전이되는 질환입니다. 유방암 환자의 증가는 비만이나 운동 부족과 같은 생활습관과 관련된 요인에 기인한 바가 크며, 모두 유방 조직에 악성 종양이 발생할 위험을 높입니다. 침윤성 유관암 치료는 가장 일반적인 유형의 유방암에 특화된 정곡을 찌른 효과적인 치료법을 제공함으로써 유방암 치료에 중요한 역할을 하고 있습니다. 이들 치료는 정밀의료를 통해 종양의 진행과 전이를 억제하고 환자의 전귀와 QOL을 향상시킵니다. 예를 들면, 미국을 거점으로 하는 비영리 단체 American Cancer Society Facts and Figures에 의하면, 유방암의 신규 환자수는 2023년의 30만 590명에서 2024년에는 31만 3,510명으로 증가했습니다. 이처럼 유방암 이환율 상승이 침윤성 유관암 치료 시장 성장에 기여하고 있습니다.
침윤성 유관암(IDC) 치료 시장의 주요 기업은 부작용을 최소화하면서 표적 치료의 정확성과 효능을 높이기 위해 항체 약물 복합체 등의 혁신적 치료법의 개발에 주력하고 있습니다. 항체약물복합체(ADC)는 항체 및 세포독성 약제를 결합한 특수한 암치료제로 건강한 조직을 온존하면서 암세포에 약제를 직접 전달할 수 있습니다. 예를 들면, 2024년 1월, 인도의 제약회사인 아스트라제네카 파마 인디아사는, 일본의 제약회사인 다이이치산쿄 주식회사와 제휴해, 트러스츠주맙 델크스테칸을 발매했습니다. 이 항체 약물 복합체는 절제 불능 또는 전이성 HER2 양성 유방암 성인 환자를 대상으로 합니다. 강력한 토포이소머라제i 저해제(deruxtecan)를 HER2 발현 암세포에 작용시켜 표적 DNA 손상과 그에 이은 세포사를 유발합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 침윤성 유관암 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 침윤성 유관암 치료 시장 : 성장률 분석
세계의 침윤성 유관암 치료 시장 실적 : 규모 및 성장(2019-2024년)
세계의 침윤성 유관암 치료 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 침윤성 유관암 치료 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 침윤성 유관암 치료 시장 : 약제 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
표적요법
호르몬 요법
세계의 침윤성 유관암 치료 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
호르몬 수용체
인간 상피 성장 인자 수용체 2(HER2)
트리플 네거티브 유방암
세계의 침윤성 유관암 치료 시장 : 최종 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
종양학 클리닉
기타 용도
세계 침윤성 유관암 치료 시장 : 표적요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
티로신 키나아제 억제제
폴리ADP 리보스 폴리머라제(PARP) 억제제
프로테아좀 억제제
세계 침윤성 유관암 치료 시장 : 호르몬 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
아로마타제 억제제
선택적 에스트로겐 수용체 조절제
에스트로겐 수용체 다운 레귤레이터
황체 형성 호르몬 방출 호르몬 작용제
제7장 지역별 및 국가별 분석
세계의 침윤성 유관암 치료 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 침윤성 유관암 치료 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
침윤성 유관암 치료 시장 : 경쟁 구도
침윤성 유관암 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck And Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Novartis International AG
AstraZeneca plc
Sanofi SA
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Gilead Sciences Inc.
Amgen Inc.
Boehringer Ingelheim
Mylan NV
Daiichi Sankyo
Astellas Pharma Inc.
Eisai Co. Ltd.
BeiGene Ltd
Dr. Reddy's Laboratories
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
침윤성 유관암 치료 시장(2029년) : 새로운 기회를 제공하는 국가
침윤성 유관암 치료 시장(2029년) : 새로운 기회를 제공하는 부문
침윤성 유관암 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Invasive ductal carcinoma (IDC) therapeutics refers to the medical treatments used to manage and treat invasive ductal carcinoma, the most common form of breast cancer that originates in the milk ducts and spreads to the surrounding breast tissue. The primary goal of these treatments is to eliminate cancer cells, prevent further spread or recurrence, and enhance patient survival and quality of life. Treatment options typically include surgery, chemotherapy, and radiation therapy.
The main drug categories in invasive ductal carcinoma therapeutics are targeted therapy and hormone therapy. Targeted therapy involves treatments that specifically focus on cancer cells by identifying certain molecular markers or genetic characteristics of the tumor, minimizing damage to healthy cells. The different types of IDC include hormone receptor-positive, human epidermal growth factor receptor 2 positive (HER2+), and triple-negative breast cancer. These therapies are primarily utilized by hospitals, oncology clinics, and other healthcare providers.
The invasive ductal carcinoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides invasive ductal carcinoma therapeutics market statistics, including the invasive ductal carcinoma therapeutics industry's global market size, regional shares, competitors with the invasive ductal carcinoma therapeutics market share, detailed invasive ductal carcinoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the invasive ductal carcinoma therapeutics market. This invasive ductal carcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The invasive ductal carcinoma therapeutics market size has grown strongly in recent years. It will grow from $8.30 billion in 2024 to $9.03 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to the rising incidence of breast cancer, increased adoption of combination therapies, growing prevalence of obesity and an aging population, expanded use of hormone receptor testing, and enhanced government support for cancer research.
The invasive ductal carcinoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $12.55 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the growing preference for personalized treatment strategies, increasing demand for minimally invasive surgical techniques, rising approvals of biosimilar monoclonal antibodies, expansion of the clinical pipeline for antibody-drug conjugates, and a stronger focus on value-based cancer care models. Key trends anticipated during the forecast period include the development of immune checkpoint inhibitors, integration of imaging and therapeutic systems, incorporation of digital health platforms into patient management, innovation in microRNA modulators, and advancements in nanoparticle-based drug delivery systems.
The increasing incidence of breast cancer is expected to drive the growth of the invasive ductal carcinoma therapeutics market in the coming years. Breast cancer is a condition in which cells within the breast multiply uncontrollably, forming a malignant tumor that can invade nearby tissues or metastasize to other parts of the body. The rise in breast cancer cases is largely attributed to lifestyle-related factors such as obesity and lack of physical activity, both of which elevate the risk of developing malignant tumors in breast tissue. Invasive ductal carcinoma therapeutics play a critical role in treating breast cancer by providing targeted and effective therapies specifically designed for the most common type of breast cancer. These treatments help limit tumor progression and spread through precision medicine, thereby enhancing patient outcomes and quality of life. For example, according to the American Cancer Society Facts and Figures, a U.S.-based nonprofit organization, the number of new breast cancer cases increased from 300,590 in 2023 to 313,510 in 2024. Thus, the rising incidence of breast cancer is contributing to the growth of the invasive ductal carcinoma therapeutics market.
Leading companies in the invasive ductal carcinoma (IDC) therapeutics market are concentrating on the development of innovative treatments, such as antibody-drug conjugates, to enhance the precision and effectiveness of targeted therapies while minimizing side effects. Antibody-drug conjugates (ADCs) are specialized cancer treatments that combine an antibody with a cytotoxic drug, allowing for the direct delivery of the drug to cancer cells while sparing healthy tissues. For example, in January 2024, AstraZeneca Pharma India Limited, an India-based pharmaceutical company, in partnership with Daiichi Sankyo Company, Limited, a Japan-based pharmaceutical firm, introduced trastuzumab deruxtecan. This antibody-drug conjugate is intended for adult patients with unresectable or metastatic HER2-positive breast cancer. It functions by directing a powerful topoisomerase I inhibitor (deruxtecan) to HER2-expressing cancer cells, leading to targeted DNA damage and subsequent cell death.
In December 2024, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to reinforce its position in the oncology sector by broadening its cancer drug portfolio, accelerating the advancement of innovative therapies, and supporting long-term growth in the cancer treatment market. Seagen Inc. is a U.S.-based biotechnology company focused on developing targeted therapies for invasive ductal carcinoma.
Major players in the invasive ductal carcinoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim, Mylan N.V., Daiichi Sankyo, Astellas Pharma Inc., Eisai Co. Ltd., BeiGene Ltd, Dr. Reddy's Laboratories, Cipla Limited, Seagen Inc., Glenmark Pharmaceuticals, and Olema Pharmaceuticals Inc.
North America was the largest region in the invasive ductal carcinoma therapeutics market in 2024. The regions covered in invasive ductal carcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the invasive ductal carcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The invasive ductal carcinoma therapeutics market consists of revenues earned by entities by providing services such as diagnostic imaging, biopsy procedures, hormone therapy, immunotherapy, and post-treatment monitoring and support care. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive ductal carcinoma therapeutics market also includes sales of diagnostic kits, biopsy tools, and medical devices used in surgical and radiation treatments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Invasive Ductal Carcinoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on invasive ductal carcinoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for invasive ductal carcinoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The invasive ductal carcinoma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Targeted Therapy; Hormone Therapy
2) By Type: Hormone Receptor; Human Epidermal Growth Factor Receptor 2 (HER2+); Triple-Negative Breast
3) By End Use: Hospitals; Oncology Clinics; Other End Uses
3. Invasive Ductal Carcinoma Therapeutics Market Trends And Strategies
4. Invasive Ductal Carcinoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Invasive Ductal Carcinoma Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Invasive Ductal Carcinoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Invasive Ductal Carcinoma Therapeutics Market Growth Rate Analysis
5.4. Global Invasive Ductal Carcinoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Invasive Ductal Carcinoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Invasive Ductal Carcinoma Therapeutics Total Addressable Market (TAM)
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Invasive Ductal Carcinoma Therapeutics Market
9.1. China Invasive Ductal Carcinoma Therapeutics Market Overview
9.2. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Invasive Ductal Carcinoma Therapeutics Market
10.1. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Invasive Ductal Carcinoma Therapeutics Market
11.1. Japan Invasive Ductal Carcinoma Therapeutics Market Overview
11.2. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Invasive Ductal Carcinoma Therapeutics Market
12.1. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Invasive Ductal Carcinoma Therapeutics Market
13.1. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Invasive Ductal Carcinoma Therapeutics Market
14.1. South Korea Invasive Ductal Carcinoma Therapeutics Market Overview
14.2. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Invasive Ductal Carcinoma Therapeutics Market
15.1. Western Europe Invasive Ductal Carcinoma Therapeutics Market Overview
15.2. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Invasive Ductal Carcinoma Therapeutics Market
16.1. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market
21.1. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market Overview
21.2. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Invasive Ductal Carcinoma Therapeutics Market
22.1. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Invasive Ductal Carcinoma Therapeutics Market
23.1. North America Invasive Ductal Carcinoma Therapeutics Market Overview
23.2. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Invasive Ductal Carcinoma Therapeutics Market
24.1. USA Invasive Ductal Carcinoma Therapeutics Market Overview
24.2. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Invasive Ductal Carcinoma Therapeutics Market
26.1. South America Invasive Ductal Carcinoma Therapeutics Market Overview
26.2. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Invasive Ductal Carcinoma Therapeutics Market
27.1. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Invasive Ductal Carcinoma Therapeutics Market
28.1. Middle East Invasive Ductal Carcinoma Therapeutics Market Overview
28.2. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Invasive Ductal Carcinoma Therapeutics Market
29.1. Africa Invasive Ductal Carcinoma Therapeutics Market Overview
29.2. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Invasive Ductal Carcinoma Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Invasive Ductal Carcinoma Therapeutics Market Competitive Landscape And Company Profiles
